Gene and cell therapy (GCT) is one of the fastest growing segments in the biopharmaceutical industry. Starting first with the approval and use for autologous CD54+ antigen presenting cells by the Food and Drug Administration (FDA), followed by several other allogeneic ...Learn More

CRISPR Co-Founder Jennifer Doudna on Future of Biotech

Dr. Zuris discussed the rationale and approach for generating a new AsCas12a variant or AsCas12 ULTRA, how the newly developed variant compares in activity and specificity against other nucleases, and its application to T and NK cell gene editing.

Designing your gRNA sequences involves 4 steps:Determining the target gene locus.Finding suitable sequences for Cas9 targeting.Checking the potential for off-target binding.Selecting gRNAs sequences that lie within your preferred binding region.GenScript's gRNA database and online ...Learn More

A minimum of 3 gRNA sequences are recommended to ensure knock-out and experimental accuracy. Independently obtained knock-out mutants provide redundancy to safeguard against any hidden off-target effects. ...Learn More